Table 2.
F-T1 | F-T3 | Prospective associations with F-T3 | Changes in F-T3 | Prospective associations with changes across peripartum (F-T3–F-T1) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | SD | M | SD | b | t | p | 95% CI | M | SD | b | t | p | 95% CI | ||||
PFB sum scorea | No AD | 68.77 | 11.40 | 68.55 | 12.46 | −0.21 | 7.90 | ||||||||||
Pure A | 69.24 | 10.89 | 66.96 | 12.19 | −0.33 | −1.17 | 0.240 | −0.91 | 0.24 | −2.28 | 7.89 | 0.00 | 0.03 | 0.978 | −0.47 | 0.48 | |
Pure D | 66.00 | 11.03 | 63.19 | 11.84 | −0.18 | −0.32 | 0.750 | −1.29 | 0.93 | −2.81 | 8.45 | −0.60 | −1.30 | 0.196 | −1.53 | 0.32 | |
Comorbid AD | 66.77 | 8.32 | 64.31 | 12.55 | −0.15 | −0.33 | 0.740 | −1.02 | 0.74 | 2.46 | 7.53 | −0.10 | −0.27 | 0.785 | −0.84 | 0.64 | |
Communicationa | No AD | 23.30 | 3.77 | 23.86 | 4.52 | 0.56 | 3.57 | ||||||||||
Pure A | 22.62 | 4.33 | 22.24 | 4.45 | −0.15 | −0.53 | 0.980 | −0.72 | 0.42 | −0.38 | 3.22 | 0.03 | 0.11 | 0.915 | −0.45 | 0.50 | |
Pure D | 21.50 | 4.03 | 22.33 | 4.40 | −0.69 | −1.25 | 0.216 | −1.8 | 0.41 | 0.83 | 2.66 | −0.64 | −1.41 | 0.163 | −1.56 | 0.27 | |
Comorbid AD | 23.00 | 3.34 | 20.69 | 0.47 | 0.62 | 0.14 | 0.889 | −0.82 | 0.94 | 2.31 | 3.59 | −0.36 | 0.719 | −0.09 | 0.60 | ||
Quarrelinga | No AD | 6.03 | 4.41 | 6.47 | 4.84 | 0.44 | 3.00 | ||||||||||
Pure A | 4.48 | 3.93 | 5.29 | 4.04 | −0.34 | 1.30 | 0.198 | −0.18 | 0.87 | 0.81 | 2.27 | 0.20 | 0.95 | 0.344 | −0.22 | 0.61 | |
Pure D | 3.83 | 2.52 | 6.00 | 5.67 | 0.27 | 0.53 | 0.597 | −0.75 | 1.29 | 2.17 | 5.41 | 0.40 | 2.80 | 0.007 | 0.32 | 1.93 | |
Comorbid AD | 5.54 | 3.57 | 4.85 | 3.95 | 0.58 | 1.42 | 0.161 | −0.23 | 1.39 | −0.69 | 2.53 | 0.32 | −0.08 | 0.940 | −0.67 | 0.61 | |
Tendernessa | No AD | 21.50 | 5.22 | 21.17 | 5.91 | −0.33 | 4.03 | ||||||||||
Pure A | 20.95 | 4.70 | 20.01 | 5.71 | −0.34 | −1.19 | 0.239 | −0.92 | 0.23 | −1.09 | 3.80 | 0.13 | 0.55 | 0.583 | −0.35 | 0.62 | |
Pure D | 18.33 | 6.84 | 16.85 | 5.98 | −0.25 | −0.44 | 0.661 | −1.36 | 0.87 | 1.48 | 3.90 | −0.07 | −0.15 | 0.884 | −1.00 | 0.87 | |
Comorbid AD | 19.31 | 4.64 | 18.46 | 6.17 | 0.25 | 0.57 | 0.569 | −0.63 | 1.14 | −0.85 | 3.11 | 0.21 | 0.57 | 0.573 | −0.53 | 0.96 | |
Satisfaction | No AD | 4.52 | 0.74 | 4.24 | 0.87 | −0.21 | 0.96 | ||||||||||
Pure A | 4.57 | 0.75 | 4.24 | 0.94 | −0.18 | −0.65 | 0.517 | −0.73 | 0.37 | 0.33 | 0.91 | 0.70 | 0.57 | 0.572 | −0.34 | 0.61 | |
Pure D | 4.42 | 0.51 | 4.18 | 0.60 | 0.72 | 1.39 | 0.170 | −0.32 | 1.77 | 0.18 | 0.60 | 0.14 | 0.12 | 0.908 | −0.86 | 0.96 | |
Comorbid AD | 4.62 | 0.51 | 4.15 | 0.80 | −1.65 | −3.97 | <0.050 | −2.48 | −0.82 | −0.46 | 0.78 | −1.02 | 0.310 | −1.16 | 0.38 |
Results based on robust regression.
PFB partnership quality questionnaire, pure A anxiety disorder only, pure D depressive disorder only, comorbid AD comorbid anxiety and depressive disorder.
b, unstandardised regression coefficient; M, mean, SD, standard deviation; t, T-Test; CI, confidence interval; p, significance level at 0.05. Bold values indicate statistical significance at p < 0.05. F–T1 week 22 to 24 of gestation; F–T2 at 10 days postpartum, F–T3 at 4 months postpartum.